CNTO 5

Drug Profile

CNTO 5

Alternative Names: CNTO-5

Latest Information Update: 16 Jan 2013

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator MorphoSys
  • Developer Janssen Biotech
  • Class Anti-inflammatories; Monoclonal antibodies
  • Mechanism of Action Immunomodulators
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I Inflammation

Most Recent Events

  • 10 Jan 2013 CNTO 5 is in phase I development in Inflammation
  • 22 Jun 2011 Centocor Ortho Biotech is now called Janssen Biotech
  • 22 Dec 2010 Centocor files application for a phase I trial of an HuCAL-derived antibody for Inflammation
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top